{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T05:40:12Z","timestamp":1736314812917,"version":"3.32.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.bulcan.2024.02.013","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T20:18:47Z","timestamp":1713298727000},"page":"S103-S110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"S","title":["Toxicit\u00e9s h\u00e9matologiques apr\u00e8s CAR-T cells, recommandations de la Soci\u00e9t\u00e9 francophone de greffe de moelle et de th\u00e9rapie cellulaire (SFGM-TC)"],"prefix":"10.1016","volume":"112","author":[{"given":"Tamim","family":"Alsuliman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clotilde","family":"Aubrun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques Olivier","family":"Bay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yves","family":"Beguin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille","family":"Bigenwald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eolia","family":"Brissot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yves","family":"Chalandon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrice","family":"Chevallier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Pagliuca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e9onardo","family":"Magro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micha","family":"Srour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.bulcan.2024.02.013_bib0260","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-Cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.bulcan.2024.02.013_bib0265","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2\u00a0ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"issue":"10343","key":"10.1016\/j.bulcan.2024.02.013_bib0270","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"10299","key":"10.1016\/j.bulcan.2024.02.013_bib0275","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19\u00a0for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2\u00a0results of the single-arm, open-label, multicentre ZUMA-3\u00a0study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"Supplement 1","key":"10.1016\/j.bulcan.2024.02.013_bib0280","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1182\/blood-2020-137156","article-title":"KarMMa-3: a phase 3\u00a0study of idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy vs standard regimens in relapsed and refractory multiple myeloma","volume":"136","author":"Delforge","year":"2020","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bulcan.2024.02.013_bib0285","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19\u00a0CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.bulcan.2024.02.013_bib0290","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.bulcan.2024.02.013_bib0295","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41409-020-0892-7","article-title":"CAR T-cell therapy for the management of refractory\/relapsed high-grade B-cell lymphoma: a practical overview","volume":"55","author":"Mohty","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bulcan.2024.02.013_bib0300","doi-asserted-by":"crossref","first-page":"1113882","DOI":"10.3389\/fimmu.2023.1113882","article-title":"The current landscape of CAR T-cell therapy for solid tumors: mechanisms, research progress, challenges, and counterstrategies","volume":"14","author":"Daei Sorkhabi","year":"2023","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.bulcan.2024.02.013_bib0305","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s11912-022-01272-6","article-title":"CAR T-cell therapy in the older person: indications and risks","volume":"24","author":"Shouse","year":"2022","journal-title":"Curr Oncol Rep"},{"issue":"3","key":"10.1016\/j.bulcan.2024.02.013_bib0310","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries in the mechanisms and functions of CAR T cells","volume":"21","author":"Larson","year":"2021","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.bulcan.2024.02.013_bib0315","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12885-021-09102-x","article-title":"Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and meta-analysis","volume":"22","author":"Luo","year":"2022","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.bulcan.2024.02.013_bib0320","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell\u2013associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.bulcan.2024.02.013_bib0325","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1182\/blood.2022017015","article-title":"Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19\u00a0CAR-T therapy for Richter-transformed DLBCL","volume":"140","author":"Rejeski","year":"2022","journal-title":"Blood"},{"issue":"38","key":"10.1016\/j.bulcan.2024.02.013_bib0330","doi-asserted-by":"crossref","first-page":"eadg3919","DOI":"10.1126\/sciadv.adg3919","article-title":"Severe hematotoxicity after CD19\u00a0CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion","volume":"9","author":"Rejeski","year":"2023","journal-title":"Sci Adv"},{"issue":"5","key":"10.1016\/j.bulcan.2024.02.013_bib0335","doi-asserted-by":"crossref","first-page":"e889","DOI":"10.1097\/HS9.0000000000000889","article-title":"An international survey on grading, diagnosis, and management of immune effector cell-associated hematotoxicity (ICAHT) following CAR T-cell therapy on behalf of the EBMT and EHA","volume":"7","author":"Rejeski","year":"2023","journal-title":"Hemasphere"},{"issue":"5","key":"10.1016\/j.bulcan.2024.02.013_bib0340","doi-asserted-by":"crossref","first-page":"e004475","DOI":"10.1136\/jitc-2021-004475","article-title":"The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19\u00a0CAR-T in R\/R LBCL","volume":"10","author":"Rejeski","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"24","key":"10.1016\/j.bulcan.2024.02.013_bib0345","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell\u2013related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bulcan.2024.02.013_bib0350","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1016\/j.bulcan.2016.09.006","article-title":"Ateliers d\u2019harmonisation des pratiques de la SFGM-TC","volume":"103","author":"Tipton","year":"2016","journal-title":"Bull Cancer"},{"issue":"20","key":"10.1016\/j.bulcan.2024.02.013_bib0355","first-page":"2460","article-title":"How i treat cytopenias after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bulcan.2024.02.013_bib0360","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/bjh.18747","article-title":"Bone marrow microenvironment disruption and sustained inflammation with prolonged haematologic toxicity after CAR T-cell therapy","volume":"202","author":"Kitamura","year":"2023","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.bulcan.2024.02.013_bib0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.12.020","article-title":"Apoptosis of hematopoietic stem cells contributes to bone marrow suppression following chimeric antigen receptor T cell therapy","volume":"29","author":"Read","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"10.1016\/j.bulcan.2024.02.013_bib0370","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/bloodadvances.2020004142","article-title":"Severe cytokine release syndrome is associated with hematologic toxicity following CD19\u00a0CAR T-cell therapy","volume":"6","author":"Juluri","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.bulcan.2024.02.013_bib0375","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the common terminology criteria for adverse events (CTCAE\u00a0\u2013\u00a0version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"issue":"12","key":"10.1016\/j.bulcan.2024.02.013_bib0380","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/j.bulcan.2021.11.001","article-title":"Prise en charge prophylactique, th\u00e9rapeutique des complications infectieuses et vaccination des patients trait\u00e9s par CAR-T cells\u00a0: recommandations de la Soci\u00e9t\u00e9 francophone de greffe de moelle et de th\u00e9rapie cellulaire (SFGM-TC)","volume":"108","author":"Paul","year":"2021","journal-title":"Bull Cancer"},{"issue":"14","key":"10.1016\/j.bulcan.2024.02.013_bib0385","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1182\/bloodadvances.2021004575","article-title":"CRP and ferritin in addition to the EASIX score predict CAR-T\u00a0\u2013\u00a0related toxicity","volume":"5","author":"Greenbaum","year":"2021","journal-title":"Blood Adv"},{"issue":"23","key":"10.1016\/j.bulcan.2024.02.013_bib0390","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1182\/bloodadvances.2021005020","article-title":"Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma","volume":"5","author":"Kennedy","year":"2021","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.bulcan.2024.02.013_bib0395","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","article-title":"Early and late hematologic toxicity following CD19\u00a0CAR-T cells","volume":"54","author":"Fried","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.bulcan.2024.02.013_bib0400","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1182\/bloodadvances.2022009019","article-title":"Effective bridging therapy can improve CD19\u00a0CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma","volume":"7","author":"Roddie","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.bulcan.2024.02.013_bib0405","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1080\/07853890.2022.2136748","article-title":"Cytopenias following anti-CD19\u00a0chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factors","volume":"54","author":"Xia","year":"2022","journal-title":"Ann Med"},{"issue":"26","key":"10.1016\/j.bulcan.2024.02.013_bib0410","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bulcan.2024.02.013_bib0415","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.bulcan.2020.11.015","article-title":"Suivi au moyen-terme des patients faisant l\u2019objet d\u2019un traitement par CAR-T cells\u00a0: recommandations de la Soci\u00e9t\u00e9 francophone de greffe de moelle et de th\u00e9rapie cellulaire (SFGM-TC)","volume":"108","author":"Alsuliman","year":"2021","journal-title":"Bull Cancer"},{"issue":"1","key":"10.1016\/j.bulcan.2024.02.013_bib0420","doi-asserted-by":"crossref","first-page":"e14157","DOI":"10.1111\/tid.14157","article-title":"Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies","volume":"25","author":"Kampouri","year":"2023","journal-title":"Transplant Infect Dis"},{"key":"10.1016\/j.bulcan.2024.02.013_bib0425","article-title":"Infectious complications of CAR T-cell therapy: a clinical update","volume":"8","author":"Stewart","year":"2021","journal-title":"Ther Adv Infect Dis"},{"issue":"10","key":"10.1016\/j.bulcan.2024.02.013_bib0430","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.cmi.2023.05.011","article-title":"Predicting infections in patients with haematological malignancies treated with chimeric antigen receptor T-cell therapies: a systematic scoping review and narrative synthesis","volume":"29","author":"Reynolds","year":"2023","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10.1016\/j.bulcan.2024.02.013_bib0435","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.seminhematol.2023.02.003","article-title":"Infectious complications of chimeric antigen receptor (CAR) T-cell therapies","volume":"60","author":"Gea-Banacloche","year":"2023","journal-title":"Semin Hematol"},{"issue":"6","key":"10.1016\/j.bulcan.2024.02.013_bib0440","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1182\/bloodadvances.2023011727","article-title":"Transfusion needs after CAR T-cell therapy for large B-cell lymphoma: predictive factors and outcome. A DESCAR-T study","volume":"8","author":"Vic","year":"2024","journal-title":"Blood Adv"},{"issue":"15","key":"10.1016\/j.bulcan.2024.02.013_bib0445","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1182\/bloodadvances.2021004554","article-title":"Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy","volume":"5","author":"Miller","year":"2021","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.bulcan.2024.02.013_bib0450","doi-asserted-by":"crossref","first-page":"e20201541","DOI":"10.1084\/jem.20201541","article-title":"Inflammation as a regulator of hematopoietic stem cell function in disease, aging, and clonal selection","volume":"218","author":"Caiado","year":"2021","journal-title":"J Exp Med"},{"key":"10.1016\/j.bulcan.2024.02.013_bib0455","doi-asserted-by":"crossref","first-page":"A183","DOI":"10.1016\/j.revmed.2016.10.222","article-title":"Sensibilisation au syndrome d\u2019activation macrophagique, l\u2019exp\u00e9rience du service de m\u00e9decine interne du CHU d\u2019Angers","volume":"37","author":"Lacout","year":"2016","journal-title":"Rev Med Interne"},{"issue":"12S","key":"10.1016\/j.bulcan.2024.02.013_bib0460","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.1016\/j.bulcan.2017.10.022","article-title":"How to manage EBV reactivation and EBV-PTLD, CMV and human herpesvirus 6\u00a0reactivation and infection after allogeneic stem cell transplantation: a report of the SFGM-TC (update)","volume":"104","author":"Brissot","year":"2017","journal-title":"Bull Cancer"},{"issue":"1","key":"10.1016\/j.bulcan.2024.02.013_bib0465","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.bulcan.2019.09.002","article-title":"Prophylaxie antivirale pour le CMV, l\u2019HSV\/VZV et le VHB apr\u00e8s allogreffe de cellules souches h\u00e9matopo\u00ef\u00e9tiques chez l\u2019adulte\u00a0: recommandations de la Soci\u00e9t\u00e9 francophone de greffe de m\u0153lle et de th\u00e9rapie cellulaire (SFGM-TC)","volume":"107","author":"Brissot","year":"2020","journal-title":"Bull Cancer"},{"key":"10.1016\/j.bulcan.2024.02.013_bib0470","doi-asserted-by":"crossref","first-page":"101141","DOI":"10.1016\/j.blre.2023.101141","article-title":"The many facets of immune-mediated thrombocytopenia: principles of immunobiology and immunotherapy","volume":"63","author":"Moulinet","year":"2024","journal-title":"Blood Rev"},{"issue":"1","key":"10.1016\/j.bulcan.2024.02.013_bib0475","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1200931","article-title":"Eltrombopag and improved hematopoiesis in refractory aplastic anemia","volume":"367","author":"Olnes","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.bulcan.2024.02.013_bib0480","doi-asserted-by":"crossref","first-page":"e149856","DOI":"10.1172\/JCI149856","article-title":"Eltrombopag inhibits TET dioxygenase to contribute to hematopoietic stem cell expansion in aplastic anemia","volume":"132","author":"Guan","year":"2022","journal-title":"J Clin Invest"},{"issue":"19","key":"10.1016\/j.bulcan.2024.02.013_bib0485","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1182\/blood-2018-11-884486","article-title":"Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-\u03b3","volume":"133","author":"Alvarado","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bulcan.2024.02.013_bib0490","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/blood.2019000358","article-title":"Romiplostim in patients undergoing hematopoietic stem cell transplantation: results of a phase 1\/2\u00a0multicenter trial","volume":"135","author":"Peffault De Latour","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bulcan.2024.02.013_bib0495","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1016\/j.bbmt.2019.12.003","article-title":"Use of thrombopoietin receptor agonists in prolonged thrombocytopenia after hematopoietic stem cell transplantation","volume":"26","author":"Mahat","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.bulcan.2024.02.013_bib0500","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1007\/s12185-015-1821-1","article-title":"Romiplostim for secondary thrombocytopenia following allogeneic stem cell transplantation in children","volume":"102","author":"Maximova","year":"2015","journal-title":"Int J Hematol"},{"issue":"9","key":"10.1016\/j.bulcan.2024.02.013_bib0505","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jtct.2023.05.012","article-title":"Efficacy and safety of CD34+ stem cell boost for delayed hematopoietic recovery after BCMA directed CAR T-cell therapy","volume":"29","author":"Davis","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.bulcan.2024.02.013_bib0255","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/bloodadvances.2022008042","article-title":"Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA\/DRST study","volume":"7","author":"Gagelmann","year":"2023","journal-title":"Blood Adv"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000745512400119X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000745512400119X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T18:51:08Z","timestamp":1736275868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000745512400119X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S000745512400119X"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2024.02.013","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxicit\u00e9s h\u00e9matologiques apr\u00e8s CAR-T cells, recommandations de la Soci\u00e9t\u00e9 francophone de greffe de moelle et de th\u00e9rapie cellulaire (SFGM-TC)","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2024.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}